MoneyWorks4Me

Marksans Pharma informs about press release

05 Nov 2025 Evaluate
Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.

The above information is a part of company’s filings submitted to BSE.  

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..